The Silent Epidemic: Science, Policy, and a Legend Tackle MASH

NEW YORK – October 29, 2026

Beneath the soaring, gilded dome of Gotham Hall, the American Liver Foundation (ALF) convened to celebrate a half-century of medical advocacy. Yet, amidst the clinking glasses and formal wear of the 50th Anniversary National Legacy Gala, the evening’s most profound moments emerged not from the celebration of past victories, but from stark confessions of human vulnerability. When Pro Football Hall of Famer Dan Marino stepped to the podium, he did not speak of gridiron conquests. Instead, he introduced the audience to a formidable, invisible opponent: Metabolic Dysfunction-Associated Steatohepatitis, or MASH.

Marino’s public disclosure of his lived experience with MASH served as a powerful anchor for an event that highlighted the rapidly evolving landscape of hepatology. As a columnist who spends her days examining how complex systems—from digital networks to public health infrastructures—impact the human spirit, I found the gala to be a masterclass in bridging the gap between clinical innovation and deeply personal resilience. The gathering illuminated a critical intersection: the point where groundbreaking biotech, rigorous federal policy, and raw human courage meet to combat a quiet epidemic.

A Hall of Famer’s Silent Opponent

For decades, liver disease has been shrouded in stigma, often unfairly associated solely with alcohol consumption. The medical community’s 2023 decision to update the nomenclature from Nonalcoholic Steatohepatitis (NASH) to MASH was a deliberate, systemic effort to destigmatize the condition and accurately reflect its metabolic roots. However, policy shifts alone cannot change public perception; it requires trusted voices to humanize the data.

MASH is widely considered a silent killer. An estimated 22 million American adults live with the condition, yet a staggering diagnostic gap exists—only about 0.15% of the adult population is formally diagnosed. The disease progressively scars the liver, often presenting no symptoms until it reaches advanced stages of cirrhosis or liver failure.

By sharing his diagnosis, Marino dismantled the isolation that so many patients feel. He emphasized the unglamorous but lifesaving daily work of managing the disease: consistency in healthy eating, maintaining well-rounded fitness routines, and fighting for a positive outlook. His plea for proactive testing is desperately needed in a healthcare ecosystem where metabolic diseases frequently go undetected.

"We were deeply honored and grateful to Dan Marino for his keynote address at ALF's 50th National Legacy Gala," said Lorraine Stiehl, CEO of American Liver Foundation and a caregiver of a transplant recipient. "His presence made ALF's Gala even more meaningful and added a special significance to this landmark celebration that brought together supporters, partners, and leaders in the field of liver disease to honor ALF's legacy while celebrating our past, present, and future. We were so appreciative for his support as we celebrated this important milestone together."

The Biotech Frontier: Mobilizing Against a Metabolic Crisis

Marino’s call to action arrives at an unprecedented inflection point in medical science. For decades, patients diagnosed with MASH were sent home with advice to lose weight and exercise, with zero FDA-approved pharmacological treatments available to halt their liver scarring. Today, the therapeutic pipeline is exploding, a shift recognized during the gala’s awards ceremony.

The ALF honored NOVO (Leadership Innovation Award) and AstraZeneca (Patient Impact Award), two pharmaceutical titans at the forefront of this metabolic revolution. NOVO’s recognition comes on the heels of the FDA’s monumental 2025 approval of semaglutide for MASH patients with moderate-to-advanced fibrosis—a breakthrough that followed the landmark 2024 approval of resmetirom. Meanwhile, AstraZeneca’s foundational partnership in the "Think Liver Think Life" public health campaign demonstrates that developing drugs is only half the battle; building public trust through community screening and education is equally vital.

Yet, as any observer of modern healthcare knows, innovation cannot reach the patient without the scaffolding of dedicated public servants and researchers. The ALF smartly utilized its 50th anniversary to honor the architects of this ecosystem. Dr. Arun Sanyal of Virginia Commonwealth University received the Leadership Award for his global role in shaping the clinical understanding of MASLD and MASH. Dr. Michael Karin of the Sanford Burnham Prebys Medical Discovery Institute was awarded the Distinguished Scientific Achievement Award for his foundational metabolic research.

Perhaps most notably, the foundation presented Leadership Awards for Public Service to Dr. Frank A. Anania of the FDA and Dr. Jay H. Hoofnagle, recently retired from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Hoofnagle’s 50-year career parallels the lifespan of the ALF itself, representing decades of federal funding and research prioritization that laid the groundwork for today’s drug approvals. Dr. Anania’s oversight at the FDA ensures that as biotech companies race to market, the safety and efficacy of these novel therapeutics remain uncompromised. Together, they represent the invisible, vital infrastructure of public trust.

Living Proof: The Human Cost and the Transplant Lifeline

Despite the wave of new therapeutics, the reality remains dire for patients whose disease has already progressed to end-stage liver failure. MASH is projected to become the leading cause of liver transplants in the United States by 2030. When preventative systems fail, the final safety net is human generosity and surgical marvel.

This reality was poignantly represented by UPMC, which received the Transplant Legacy Award. As the nation’s leading transplant center conducting the highest volume of living-donor liver transplants, UPMC stands at the bleeding edge of a logistical and ethical frontier. With the national waitlist far outpacing the supply of deceased donor organs, living-donor programs are a critical lifeline, demanding extraordinary medical precision and profound human sacrifice.

The human spirit driving these statistics was personified by Peter Cullen, an entrepreneur and former Disney and ABC executive who received the inaugural Michael Kerr Volunteer of the Year Award. Diagnosed with primary sclerosing cholangitis (PSC), Cullen’s journey is a testament to endurance. After a living-donor transplant from his brother failed to thrive, Cullen endured a grueling decade of medical interventions before receiving a second, life-saving transplant from a deceased donor in 2016. Rather than retreating into quiet recovery, Cullen channeled his trauma into advocacy, spearheading the ALF’s strategic rebranding and creating "Bili the Brave," a children's book for families navigating biliary atresia.

Similar resilience was echoed by ALF's LIVEr Champion Tommy Nolan, a U.S. Navy veteran and former NYPD sergeant. For years, Nolan lived with PSC—a rare, incurable autoimmune liver disease discovered only after a routine doctor's appointment revealed elevated enzymes. His complex, life-saving transplant in 2023 stands as a testament to the quiet battles fought by millions of Americans navigating chronic illness.

The evening's emotional resonance was further deepened by the 2026 National Legacy Gala Chair, Samantha Kellner. Her advocacy was born in the crucible of a parent's worst nightmare: her infant son, Raphael, required a life-saving transplant for biliary atresia within eight weeks of his birth. Two decades later, the Kellner Pediatric Liver Foundation continues to advocate fiercely for children. Her family's story, interwoven with the narratives of Marino, Cullen, and Nolan, served as a powerful reminder that behind every clinical trial, every FDA approval, and every epidemiological statistic, there are families fighting for simply one more tomorrow.